Cargando…

Endocrine therapy initiation and overall survival outcomes with omission of radiation therapy in older Medicare patients with early‐stage hormone‐receptor‐positive breast cancer

BACKGROUND: Guidelines allow for the omission of radiotherapy in older women with early‐stage, hormone‐receptor‐positive breast cancer, given that the patients receive adequate endocrine therapy (ET). However, the initiation of ET and survival outcomes after forgoing radiation therapy among these pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Chan, Li, Ning, Zhou, Shouhao, Stahl, Kelly, Dodge, Daleela, Zhao, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067080/ https://www.ncbi.nlm.nih.gov/pubmed/36428284 http://dx.doi.org/10.1002/cam4.5488

Ejemplares similares

Controversies of radiation therapy omission in elderly women with early stage invasive breast cancer
por: Abu-Gheida, Ibrahim, et al.
Publicado: (2020)

Trends and patterns in the use of opioids among metastatic breast cancer patients
por: Shen, Chan, et al.
Publicado: (2020)

Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors
por: Camacho, Fabian T., et al.
Publicado: (2017)

Preserving choice in breast cancer treatment: A different perspective on contralateral prophylactic mastectomy
por: Pender, Kelly, et al.
Publicado: (2023)

Omission
Publicado: (1881)

An Omission
Publicado: (1885)

Omission
Publicado: (1867)

Omission
Publicado: (1882)

An Omission
Publicado: (1875)

Omission
Publicado: (1858)

Adjuvant radiation therapy alone is associated with improved overall survival compared to hormonal therapy alone in older women with estrogen receptor positive early stage breast cancer
por: Jhawar, Sachin R., et al.
Publicado: (2020)

Omission of adjuvant therapy in stage I clear cell ovarian cancer: Review of the BC Cancer experience
por: Liu, Shiru L., et al.
Publicado: (2019)

Effect of omission of surgery on survival in patients aged 80 years and older with early‐stage hormone receptor‐positive breast cancer
por: de Boer, A. Z., et al.
Publicado: (2020)

Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2020)

Omission of Affiliations
Publicado: (2019)

Omission in Supplement
Publicado: (2019)

Omission in Funding
Publicado: (2022)

Omission in Title
Publicado: (2022)

Omission of Subtitle
Publicado: (2022)

Association of Endocrine Therapy With Overall Survival in Women With Small, Hormone Receptor–Positive, ERBB2-Negative Breast Cancer
por: Ma, Sung Jun, et al.
Publicado: (2020)

Shifts in endocrine homeostasis and preventive hormone replacement therapy: extending the Women’s Health Initiative globally
por: Ball, Jacob D., et al.
Publicado: (2016)

Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
por: Cho, Beomyoung, et al.
Publicado: (2022)

Omissions and Byproducts across Moral Domains
por: DeScioli, Peter, et al.
Publicado: (2012)

Salient omissions—pupil dilation in response to unexpected omissions of sound and touch
por: Dercksen, Tjerk T., et al.
Publicado: (2023)

Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women
por: Pritchard, Kathleen
Publicado: (2005)

Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ
por: Anderson, Chelsea, et al.
Publicado: (2017)

Omission in Funding/Support
Publicado: (2020)

The role of hormonal factors and endocrine therapy in ovarian cancer
por: Serkies, Krystyna, et al.
Publicado: (2013)

Consequences on islet and incretin hormone responses to dinner by omission of lunch in healthy men
por: Lindgren, Ola, et al.
Publicado: (2020)

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review
por: Reinert, Tomás, et al.
Publicado: (2017)

Suggestion for the omission of post-mastectomy chest wall radiation therapy in patients who underwent skin-sparing/nipple-sparing mastectomy
por: Kim, Nalee, et al.
Publicado: (2022)

Assessment of Oncologists’ Perspectives on Omission of Sentinel Lymph Node Biopsy in Women 70 Years and Older With Early-Stage Hormone Receptor–Positive Breast Cancer
por: Minami, Christina A., et al.
Publicado: (2022)

Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma
por: Shen, Chan, et al.
Publicado: (2022)

Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation
por: Johnston, Simon J., et al.
Publicado: (2018)

Correlates of Insulin Injection Omission
por: Peyrot, Mark, et al.
Publicado: (2010)

Clinical Omissions in COVID-19
por: Quinn, MJ
Publicado: (2021)

Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations
por: Nattinger, Ann Butler, et al.
Publicado: (2015)

Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
por: Bian, Li, et al.
Publicado: (2020)

Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer
por: Sjöström, Martin, et al.
Publicado: (2023)

Can Infinitival to Omissions and Provisions Be Primed? An Experimental Investigation Into the Role of Constructional Competition in Infinitival to Omission Errors
por: Kirjavainen, Minna, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8aqbbvvk1u5pqjr6ps20sjcrsl